

1. Vasaturo A, Di Blasio S, Verweij D, **Blokx** WA, Krieken JH, Vries IJM, Figdor CG: Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma. *Histopathology* 2017, 70:643–649.
2. Semango G, Heinhuis B, Plantinga TS, **Blokx** WA, Kibiki G, Sonda T, Mavura D, Masenga EJ, Nyindo M, van der Ven AJ: Exploring the Role of IL-32 in HIV-Related Kaposi Sarcoma. *The American journal of pathology* 2017, 188(1):196-203.
3. van Engen-van Grunsven AC, Rabold K, Küsters-Vandeveldel HV, Rijntjes J, Djafarihamedani M, Hehir-Kwa JY, Willemsen MA, van der Burgt I, Wesseling P, **Blokx** WA: Genomic analysis of leptomeningeal and skin melanocytic tumors in neurocutaneous melanosis; potential clues for diagnosis and prognosis. *Genetic alterations in rare subtypes of melanocytic tumors* 2017, 125.
4. Volker Touw C, Koning HD, Giltay JC, Kovel C, Kempen TS, Oberndorff K, Boes ML, Steensel M, Well G, **Blokx** W: Erythematous nodes, urticarial rash and arthralgias in a large pedigree with NLRC4-related autoinflammatory disease, expansion of the phenotype. *British Journal of Dermatology* 2017, 176:244–248.
5. Janssen L, Brons P, Schreuder H, **Blokx** W, Deurloo EE, Bos C: Image Gallery: A rare abscess-like presentation of Langerhans cell histiocytosis. *British Journal of Dermatology* 2017, 176(4):e33.
6. Cook MG, Massi D, **Blokx** WA, Van den Oord J, Koljenović S, De Giorgi V, Kissin E, Grant M, Mandal A, Gremel G: New insights into naevoid melanomas: a clinico-pathological reassessment. *Histopathology* 2017, 71(6):943-50.
7. Hoogedoorn L, Hendriks J, Knuiman GJ, **Blokx** W, Kerkhof P, Erp P, Gerritsen M: Treatment failure in superficial basal cell carcinoma following treatment with photodynamic therapy: is this a result of underdiagnosis? *Journal of the European Academy of Dermatology and Venereology* 2017, 31(1):e50-e52.
8. Teunissen BT, Knuiman GJ, Eijkelenboom A, Wauters C, Wouda S, **Blokx** W: CTNNB1-mutated melanocytic lesions with DPN like features: a distinct subtype of melanocytic tumors? A report of two cases. *Virchows Archiv* 2017, 1–5.
9. van Vugt LJ, van der Vleuten CJ, Flucke U, **Blokx** WA: The utility of GLUT1 as a diagnostic marker in cutaneous vascular anomalies: A review of literature and recommendations for daily practice. *Pathology, research and practice* 2017, 213:591–597.
10. Nguyen KP, Knuiman GJ, Van Erp PE, **Blokx** WA, Peppelman M, Gerritsen M-JP: Standard step sectioning of skin biopsy specimens diagnosed as superficial basal cell carcinoma frequently yields deeper and more aggressive subtypes. *Journal of the American Academy of Dermatology* 2017, 76:351–353.
11. Küsters-Vandeveldel HV, Creytens D, Van Engen-van Grunsven AC, Jeunink M, Winnepenninckx V, Groenen PJ, Küsters B, Wesseling P, **Blokx** WA, Prinsen CF: SF3B1 and EIF1AX mutations occur in primary leptomeningeal melanocytic neoplasms; yet another similarity to uveal melanomas. *Acta Neuropathologica Communications* 2016, 15:4:5.
12. Wolberink E, Peppelman M, **Blokx** W, Van De Kerkhof P, Van Erp P, Gerritsen M: In vivo diagnosis of basal cell carcinoma subtype by reflectance confocal microscopy. *In vivo reflectance confocal microscopy* 2016, 227:119
13. Vasaturo A, Halilovic A, Bol K, Verweij D, Groenen P, van Krieken H, **Blokx** W, de Vries J, Textor J, Figdor CG: Abstract A016: T cell landscape within primary melanoma as a predictive biomarker of survival after cancer vaccination in patients with metastatic disease. *Cancer research* 2016, 15:76(12):3496-506.
14. Halilovic A, Vasaturo A, Bol K, Verweij D, **Blokx** W, Punt C, Groenen P, van Krieken H, Textor J, de Vries J: T cell landscape in primary melanoma predicts the survival of patients with metastatic disease after their treatment with dendritic cell vaccines. 2016, 469:S44–S44.
15. Bosisio FM, Wilmott JS, Volders N, Mercier M, Wouters J, Stas M, **Blokx** WA, Massi D, Thompson JF, Scolyer RA: Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. *Modern Pathology* 2016, 29:347–358.
16. Bol KF, Aarntzen EH, Pots JM, Nordkamp MAO, van de Rakt MW, Scharenborg NM, de Boer AJ, van Oorschot TG, Croockewit SA, **Blokx** WA: Prophylactic vaccines are potent activators of

- monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. *Cancer Immunology, Immunotherapy* 2016, 65:327–339.
17. Vasaturo A, Halilovic A, Bol KF, Verweij DI, **Blokk** WA, Punt CJ, Groenen PJ, van Krieken JHJ, Textor J, de Vries IJM: T-cell landscape in a primary melanoma predicts the survival of patients with metastatic disease after their treatment with dendritic cell vaccines. *Cancer Research* 2016, 76:3496–3506.
 18. Küsters-Vandeveldel HV, van Engen-van Grunsven IA, Coupland SE, Lake SL, Rijntjes J, Pfundt R, Küsters B, Wesseling P, **Blokk** WA, Groenen PJ: Mutations in g protein encoding genes and chromosomal alterations in primary leptomeningeal melanocytic neoplasms. *Pathology & Oncology Research* 2015, 21:439–447
 19. Hoogedoorn L, Peppelman M, **Blokk** W, Erp P, Gerritsen MJ: Prospective differentiation of clinically difficult to distinguish nodular basal cell carcinomas and intradermal nevi by non-invasive Reflectance Confocal Microscopy: a case series study. *Journal of the European Academy of Dermatology and Venereology* 2015, 29:330–336.
 20. Küsters-Vandeveldel HV, Küsters B, Engen van Grunsven AC, Groenen PJ, Wesseling P, **Blokk** WA: Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects. *Brain Pathology* 2015, 25:209–226.
 21. Buimer MG, Wobbles T, Klinkenbijn JH, Reijnen MM, **Blokk** WA: Immunohistochemical analysis of steroid hormone receptors in hidradenitis suppurativa. *The American Journal of Dermatopathology* 2015, 37:129–132.
 22. van Engen-van Grunsven AC, Baar MP, Pfundt R, Rijntjes J, Küsters-Vandeveldel HV, Delbecq A-L, Keunen JE, Klevering JB, Wesseling P, **Blokk** WA: Whole-genome copy-number analysis identifies new leads for chromosomal aberrations involved in the oncogenesis and metastatic behavior of uveal melanomas. *Melanoma Research* 2015, 25:200–209.
 23. Vasaturo A, Halilovic A, Bol K, Verweij D, **Blokk** W, Groenen P, van Krieken H, Textor J, de Vries J, Figdor C: T cell landscape within primary melanoma as a biomarker of survival after cancer vaccination in patients with metastatic disease. *Journal for ImmunoTherapy of Cancer* 2015, 3:P420.
 24. de Waal Y, **Blokk** W, Mommers JM, Hilbrands LB: A purple finger two months after kidney transplantation. *Netherlands Journal of Medicine* 2015;73(2):92, 95.
 25. Keijmel SP, van Kasteren M, **Blokk** W, van der Meer J, van Rossum M, Bleeker-Rovers CP: Cutaneous hyperpigmentation induced by doxycycline: a case series. *Netherlands Journal of Medicine* 2015, 73:37–40.
 26. **Blokk** WA, Rabold K, Bovenschen HJ, Ligtenberg MJ, Mensenkamp AR, van Lijnschoten G, van Zelst-Stams WA, Groenen PJ: NRAS-mutated melanocytic BAP1-associated intradermal tumor (MBAIT): a case report. *Virchows Archiv* 2015, 466:117–121.
 27. Bekers EM, van Engen-van Grunsven AC, Groenen PJ, Westdorp H, Koornstra RH, Bonenkamp JJ, Flucke U, **Blokk** WA: Metastatic melanoma mimicking solitary fibrous tumor: report of two cases. *Virchows Archiv* 2014, 464:247–251
 28. van Engen-van Grunsven AC, Küsters-Vandeveldel HV, De Hullu J, van Duijn LM, Rijntjes J, Bovée JV, Groenen PJ, **Blokk** WA: NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract—a study of 24 cases from the Netherlands. *Gynecologic Oncology* 2014, 134:10–14.
 29. Van Geel MJ, Wijnen M, Hoppenreijns EP, Gierenz N, Spruijt L, van Kool-Wijk M, Flucke U, **Blokk** WA, Seyger M: Hypertrophic Left Calf and Multiple Flesh-coloured Subcutaneous Tumours in a 5-year-old Girl: A Quiz. *Acta Dermato Venereologica* 2014, 94:619–620
 30. de Koning HD, van Vlijmen-Willems IM, Zeeuwen PL, **Blokk** WA, Schalkwijk J: Absent in Melanoma 2 is predominantly present in primary melanoma and primary squamous cell carcinoma, but largely absent in metastases of both tumors. *Journal of the American Academy of Dermatology* 2014, 71:1012–1015.
 31. De Waal AC, Vossen R, Aben K, Kiemeny L, van Rossum MM, **Blokk** W: Limited role for histopathological examination of re-excision specimens of completely excised melanomas. *Virchows Archiv* 2014, 465:225–231.

32. van Engen-van Grunsven AC, Kusters-Vandeveld H, Groenen PJ, **Blokx** WA: Update on molecular pathology of cutaneous melanocytic lesions: what is new in diagnosis and molecular testing for treatment? *Frontiers in Medicine* 2014, 31 October 2014.
33. Waal AC, Harten Gerritsen AS, Aben K, Kiemeney L, Rossum MM, **Blokx** W: Impact of mitotic activity on the pathological substaging of pT1 cutaneous melanoma. *British Journal of Dermatology* 2014, 170:874–877.
34. Dubbink HJ, Deans ZC, Tops BB, van Kemenade FJ, Koljenović S, van Krieken HJ, **Blokx** WA, Dinjens WN, Groenen PJ: Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe. *Molecular Oncology* 2014, 8:830–839.
35. Peppelman M, Wolberink EA, **Blokx** WA, Van De Kerkhof PC, Van Erp PE, Gerritsen M-JP: In vivo diagnosis of basal cell carcinoma subtype by reflectance confocal microscopy. *Dermatology* 2013, 227:255–262.
36. Peppelman M, Wolberink E, van de Kerkhof P, **Blokx** W, van Erp P, Gerritsen M: Non-invasive diagnosis of basal cell carcinoma subtype by reflectance confocal microscopy. 2013, 133:S160–S160.
37. **Blokx** W, Groenen P: Moleculaire diagnostiek bij melanoom: meer dan BRAF-V600E en vemurafenib. 2013, *nederlands Tijdschrift voor Oncologie*;10(7):281–289.
38. Driessen C, van Rossum MM, **Blokx** W, van Herpen C: Skin lesions in a patient with head and neck cancer. *The Netherlands journal of medicine* 2013, 71:481–485.
39. Ham ten JC, Blokx W, Drenth J: Gecompliceerde levercyste?! *Lever* 2013, 4:11–12.
40. De Waal AC, **Blokx** WA, Seyger M, van Rossum MM: Elastoderma: an uncommon cause of acquired hyperextensible skin. *Acta Dermato Venereologica* 2012, 92:328–329.
41. De Waal AC, Gerritsen AS, Aben KK, Kiemeney LA, van Rossum MM, **Blokx** WA: Impact of adding mitotic activity to the pathological staging protocol in pt1 cutaneous melanoma. *Pigment Cell & Melanoma Research* 2012, 25:902.
42. Sparreboom E, Wetzels C, Verdijk M, Mulder S, **Blokx** W: Subcutaneous angiomatoid fibrous histiocytoma mimicking metastatic melanoma. *Case reports in pathology* 2012, 2012:291623.
43. van der Zwan JM, Siesling S, **Blokx** W, Pierie J, Capocaccia R: Invasive extramammary Paget's disease and the risk for secondary tumours in Europe. *European Journal of Surgical Oncology (EJSO)* 2012, 38:214–221.
44. Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, De Wilt JH, van Rossum MM, **Blokx** WA, Jacobs JF, Duiveman-de Boer T: Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. *Clinical Cancer Research* 2012, 18:5460–5470.
45. Boers-Sonderen MJ, Desai IM, **Blokx** W, Timmer-Bonte JN, van Herpen CM: A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244). *Anti-cancer drugs* 2012, 23:761–764.
46. Aarntzen EH, Srinivas M, De Wilt JH, Jacobs JF, Lesterhuis WJ, Windhorst AD, Troost EG, Bonenkamp JJ, van Rossum MM, **Blokx** WA: Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F] FLT) PET imaging. *Proc Natl Acad Sci U S A* 2011, 108:18396–18399.
47. Bogenrieder T, van Dijk MR, **Blokx** WA, Ramrath K, Seldenrijk K, Stolz W, van Diest PJ: No non-sentinel node involvement in melanoma patients with limited Breslow thickness and low sentinel node tumour load. *Histopathology* 2011, 59:318–326.
48. Groenen PJ, **Blokx** WA, Diepenbroek C, Burgers L, Visinoni F, Wesseling P, van Krieken JH: Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. *Histopathology* 2011, 59:1–7
49. van Engen-van Grunsven AC, van Dijk MC, Ruiter DJ, Klaasen A, Mooi WJ, **Blokx** WA: HRAS-mutated Spitz tumors: a subtype of Spitz tumors with distinct features. 34 2010, 34:1436–1441.
50. Küsters-Vandeveld HV, van Engen-van Grunsven IA, Küsters B, van Dijk MR, Groenen PJ, Wesseling P, **Blokx** WA: Improved discrimination of melanotic schwannoma from melanocytic lesions by combined morphological and GNAQ mutational analysis. *Acta Neuropathologica* 2010, 120:755–764

51. Küsters-Vandeveldel HV, Van Leeuwen A, Verdijk MA, de Koning MN, Quint WG, Melchers WJ, Ligtenberg MJ, **Blokx** WA: CDKN2A but not TP53 mutations nor HPV presence predict poor outcome in metastatic squamous cell carcinoma of the skin. *International Journal of Cancer* 2010, 126:2123–2132.
52. Küsters-Vandeveldel HV, Klaasen A, Küsters B, Groenen PJ, van Engen-van Grunsven IA, van Dijk MR, Reifengerber G, Wesseling P, **Blokx** WA: Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. *Acta Neuropathologica* 2010, 119:317–323.
53. **Blokx** WAM, Van Dijk MC, Ruiter DJ: Molecular cytogenetics of cutaneous melanocytic lesions—diagnostic, prognostic and therapeutic aspects. *Histopathology* 2010, 56:121–132.
54. Küsters B, van Engen-van Grunsven I, Groenen P, van Dijk M, Wesseling P, **Blokx** W, Küsters-vandeveldel H: Gnaq mutation analysis might be useful in distinguishing between primary melanocytic lesions of the Cns and melanotic schwannomas. *Brain Pathology* 2010, 20:61.
55. Kleinpenning MM, Wolberink EW, Smits T, **Blokx** WA, Van De Kerkhof P, Van Erp PE, Gerritsen RM: Fluorescence diagnosis in actinic keratosis and squamous cell carcinoma. *Photodermatology, Photoimmunology & Photomedicine* 2010, 26:297–302.
56. Molenaar JP, Baten A, **Blokx** WA, Hoogendam A: Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate. *European Urology* 2009, 56:874–877.
57. van der Velden HM, van Rossum MM, **Blokx** WA, Boezeman J, Gerritsen M-JP: Clinical characteristics of cutaneous melanoma and second primary malignancies in a dutch hospital-based cohort of cutaneous melanoma patients. *Dermatology Research and Practice* 2009, 2009:479183.
58. Stol K, van Selm S, van den Berg S, Bootsma HJ, **Blokx** W, Graamans K, Tonnaer E, Hermans P: Development of a non-invasive murine infection model for acute otitis media. *Microbiology* 2009, 155:4135–4144.
59. Wetzels CT, Hoefnagel JG, Bakkers JM, Dijkman HB, **Blokx** WA, Melchers WJ: Ultrastructural proof of polyomavirus in Merkel cell carcinoma tumour cells and its absence in small cell carcinoma of the lung. *PloS one* 2009, 4:e4958.
60. Jacobs JF, Aarntzen EH, Sibelt LA, **Blokx** WA, Boullart AC, Gerritsen M-J, Hoogerbrugge PM, Figdor CG, Adema GJ, Punt CJ: Vaccine-specific T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. PDF hosted at the Radboud Repository of the Radboud University Nijmegen 2009, 58:83.
61. Velden WVD, Lesterhuis J, **Blokx** W, Schattenberg A: Isolated acral dermatitis due to graft-versus-host disease. *European Journal of Haematology* 2009, 82:326–326.
62. Küsters-Vandeveldel HV, de Koning MN, Melchers WJ, Quint WG, de Wilde P, de Jong EM, van de Kerkhof P, **Blokx** WA: Expression of p14ARF, p16INK4a and p53 in relation to HPV in (pre-) malignant squamous skin tumours. *J Cell Mol Med* 2009, 13:2148–2157
63. Jacobs JF, Aarntzen EH, Sibelt LA, **Blokx** WA, Boullart AC, Gerritsen M-J, Hoogerbrugge PM, Figdor CG, Adema GJ, Punt CJ: Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. *Cancer Immunology, Immunotherapy* 2009, 58:145.
64. Kuesters-Vandeveldel HV, Van Leeuwen A, Verdijk MA, de Koning MN, Quint WG, Melchers WJ, Ligtenberg MJ, **Blokx** WA: CDKN2A and TP53 mutational analysis in metastatic squamous cell carcinoma of the skin. 2008, 452:S103–S103.
65. Boone B, **Blokx** W, De Bacquer D, Lambert J, Ruiter D, Brochez L: The role of VEGF-C staining in predicting regional metastasis in melanoma. *Virchows Archiv* 2008, 453:257–265.
66. D'hauw A, Seyger M, Groenen P, Weemaes C, Warris A, **Blokx** W: Cutaneous graft-versus-host-like histology in childhood. Importance of clonality analysis in differential diagnosis. A case report. *British Journal of Dermatology* 2008, 158:1153–1156.
67. Ruiter DJ, van Dijk M, Mol S, Klaasen A, Ligtenberg M, **Blokx** W: Cs14-1 Mutation analysis and gene copy number detection as diagnostic aids in the assessment of melanocytic tumors. *Pigment Cell & Melanoma Research* 2008, 21:270.
68. Overbeek LI, Ligtenberg MJ, Willems RW, Hermens RP, **Blokx** WA, Dubois SV, van der Linden H, Meijer JW, Mlynek-Kersjes ML, Hoogerbrugge N: Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. *34* 2008, 32:1246–1251.

69. Van Dijk M, Aben K, van Hees F, Klaasen A, **Blokk** W, Kiemeney L, Ruiter DJ: Expert review remains important in the histopathological diagnosis of cutaneous melanocytic lesions. *Histopathology* 2008, 52:139–146.
70. Van Laarhoven H, Blokk W, Seyger M, Koopmans PP: A patient with abdominal pain and a rash. 2008, *Netherlands Journal of Medicine*;66(1):48-9.
71. Sibelt L, Aboosy N, Van Der Velden W, Blijlevens N, Blokk W, Seyger M: Palifermin-induced flexural hyperpigmentation: a clinical and histological study of five cases. *British Journal of Dermatology* 2008, 159:1200–1203.
72. Küsters-Vandeveldde HV, Keunen JE, Wesseling P, Verdijk MA, Ligtenberg MJ, **Blokk** WA: Occurrence of ocular melanoma thirteen years after skin melanoma: two separate primaries or metastatic disease? A case solved with NRAS and CDKN2A (INK4A-ARF) mutational analysis. *Virchows Archiv* 2008, 452:331–336.
73. De Jager M, **Blokk** W, Warris A, Bergers M, Link M, Weemaes C, Seyger M: Immunohistochemical features of cutaneous granulomas in primary immunodeficiency disorders: a comparison with cutaneous sarcoidosis. *Journal of cutaneous pathology* 2008, 35:467–472.
74. Kroft E, Melchers W, **Blokk** W, De Hoop D, Warris A: A generalized skin eruption in a human immunodeficiency virus–infected boy. *Journal of the European Academy of Dermatology and Venereology* 2008, 22:896–897.
75. Bogenrieder T, van Dijk MC, **Blokk** W, Stolz W, van Diest PJ: Absence of second echelon involvement in melanoma patients with limited Breslow thickness and low sentinel node tumor load. *Journal of Clinical Oncology* 2008, 26:9060–9060.
76. Koetsier M, **Blokk** W, van Dooren-Greebe RJ, Janssens R: Atypisch fibroxanthoom. *Dermatologie Venereologie* 2007, 298.
77. Senff NJ, Hoefnagel JJ, Jansen PM, Vermeer MH, van Baarlen J, **Blokk** WA, Canninga-van Dijk MR, Geerts M-L, Hebeda KM, Kluin PM: Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO–EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. *Journal of Clinical Oncology* 2007, 25:1581–1587.
78. Laverman P, **Blokk** WA, Morsche Te RH, Frielink C, Boerman OC, Oyen WJ, Drenth JP: [18F] FDG accumulation in an experimental model of multistage progression of cholangiocarcinoma. *Hepatology Research* 2007, 37:127–132.
79. Siesling S, Elferink M, van Dijk J, Pierie J, **Blokk** W: Epidemiology and treatment of extramammary Paget disease in the Netherlands. *European Journal of Surgical Oncology (EJSO)* 2007, 33:951–955.
80. Smits T, Olthuis D, **Blokk** WA, Kleinpenning MM, Van De Kerkhof P, Van Erp PE, Gerritsen M-JP: Aneuploidy and proliferation in keratinocytic intraepidermal neoplasias. *Experimental Dermatology* 2007, 16:81–86.
81. de Jager M, Weemaes C, **Blokk** W, Seyger M: Niet-infectieuze cutane granulomen bij een kind met een primaire immuundeficiëntie. *Dermatologie Venereologie* 2007, 169.
82. Kroft E, Haneke E, Pruszczynski M, **Blokk** W, Pasch MC: Een zeldzame subunguale tumor. *Dermatologie Venereologie* 2007, 169.
83. Vissers W, Zeeuwen-Franssen M, van Haselen CW, **Blokk** W, Gerritsen M: Valkuilen bij de diagnostiek van melanoom: twee casus met atypische presentatie van (lentigo maligna) melanoom. *Dermatologie en Venereologie* 2007, 169.
84. Sibelt L, **Blokk** W, Smilde TJ, Gerritsen M: “En cuirasse”metastasen bij lobulair mammacarcinoom. *Nederlands Tijdschrift voor Dermatologie & Venereologie* 2007, 17:189–191.
85. Smits T, Kleinpenning MM, **Blokk** WA, van de Kerkhof PC, van Erp PE, Gerritsen M-JP: Fluorescence diagnosis in keratinocytic intraepidermal neoplasias. *Journal of the American Academy of Dermatology* 2007, 57:824–831.
86. Smits T, Kleinpenning MM, **Blokk** W, Van De Kerkhof P, Van Erp P, Gerritsen M, Wolberink EW: Fluorescence diagnosis and photodynamic therapy for non-melanoma skin cancer. PDF hosted at the Radboud Repository of the Radboud University Nijmegen 2007, 57:57.

87. **Blokx** WA, Lesterhuis WJ, Andriessen MP, Verdijk MA, Punt CJ, Ligtenberg MJ: CDKN2A (INK4A-ARF) mutation analysis to distinguish cutaneous melanoma metastasis from a second primary melanoma. *34* 2007, 31:637–641.
88. Peters B, **Blokx** W, Seyger M: Langerhanscelhistiocytosis. *Nederlands Tijdschrift voor Dermatologie & Venereologie* 2007.
89. **Blokx** W, Lesterhuis JJ, Andriessen M, Verdijk M, Punt K, Ligtenberg M: CDKN2A (INK4A-ARF) mutation analysis to distinguish cutaneous melanoma metastasis from a second primary melanoma (vol 4, pg 637, 2007). *34* 2007, 31:1137–1137.
90. Peters B, **Blokx** W, Seyger M: Clinicopathologische correlatie. *Nederlands Tijdschrift voor Dermatologie & Venereologie* 2007, 309.
91. **Blokx** W, Van Dijk M, Ruiter DJ: Spitzoïde melanocytair laesies: weinig consensus en veel controverses: Hoe krijgen we het spits? *Nederlands Tijdschrift voor Dermatologie & Venereologie* 2007.
92. van Dijk M, **Blokx** W, Ruiter D: Molecular classification of spitzoid melanocytic lesions: distinct mutations and chromosomal gains and losses. *Melanoma Research* 2006, 16:S62–S63.
93. Zandbelt MM, **Blokx** WA, DeJong EM, Van de Putte L, Van den Hoogen F: Expression of estrogen receptors alpha and beta in skin and salivary gland biopsy specimens of Sjogren's syndrome patients. 2006, 65:482–483
94. Prins M, **Blokx** W, Seijger M: Congenitaal dermafibrosarcoma protuberans. *Nederlands Tijdschrift voor Dermatologie & Venereologie* 2005, 15:188–191
95. Franssen M, **Blokx** W, Seijger M: Palissaderende neutrofiële granulomateuze dermatitis. *Nederlands Tijdschrift voor Dermatologie & Venereologie* 2005.
96. Hendriks S, de Wilde P, Kaanders J, **Blokx** W, Poorter RL, Merks M: Merkel cell carcinoma in the oral cavity: a case presentation and review of the literature. *Oral Oncology Extra* 2005, 41:202–206
97. van Lingen RG, Bol M, **Blokx** W, Vissers W, van der Valk P, Seijger M: Het syndroom van Wells op kinderleeftijd. *Nederlands Tijdschrift voor Dermatologie & Venereologie* 2005, 15:360–363
98. de Jongh GJ, Zeeuwen PL, Kucharekova M, Pfundt R, van der Valk PG, **Blokx** W, Dogan A, Hiemstra PS, van de Kerkhof PC, Schalkwijk J: High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. *Journal of Investigative Dermatology* 2005, 125:1163–1173.
99. Smit JV, van Rossum MM, **Blokx** W, Bauland CG, Gerritsen M: Basaalcelcarcinoom en trichoepitheliom. *Nederlands Tijdschrift voor Dermatologie & Venereologie* 2005, 15:201–203.
100. de Jongh GJ, Keulers BJ, Spauwen P, **Blokx** W, Gerritsen M: A skin tumor as a marker for a hereditary cancer syndrome: Muir-Torre syndrome. *European Journal of Plastic Surgery* 2005, 28:276–280.
101. **Blokx** WA, Ruiter DJ, Verdijk MA, de Wilde PC, Willems RW, de Jong EMJ, Ligtenberg MJ: INK4-ARF and p53 mutations in metastatic cutaneous squamous cell carcinoma: case report and archival study on the use of Ink4a-ARF and p53 mutation analysis in identification of the corresponding primary tumor. *34* 2005, 29:125–130.
102. Van Iersel CA, Van de Velden H, Kusters C, Spauwen P, **Blokx** W, Kiemeny L, Gerritsen M: Prognostic factors for a subsequent basal cell carcinoma: implications for follow-up. *British Journal of Dermatology* 2005, 153:1078–1080.
103. van Rossum MM, Haneke E, **Blokx** W, Seijger M: Leukemia cutis met mucine-depositie bij een myelodysplastisch syndroom. *Nederlands Tijdschrift voor Dermatologie & Venereologie* 2005, 15:191–193.
104. van Kempen LC, Rijntjes J, Claes A, **Blokx** WA, Gerritsen M-JP, Ruiter DJ, van Muijen GN: Type I collagen synthesis parallels the conversion of keratinocytic intraepidermal neoplasia to cutaneous squamous cell carcinoma. *The Journal of pathology* 2004, 204:333–339.
105. Smit JV, de Sévaux RG, **Blokx** WA, van de Kerkhof PC, Hoitsma AJ, de Jong EM: Acitretin treatment in (pre) malignant skin disorders of renal transplant recipients: Histologic and immunohistochemical effects. *Journal of the American Academy of Dermatology* 2004, 50:189–196.

106. van Steensel MA, Steijlen PM, Jansen BJ, **Blokk** W, van de Kerkhof PC, Happle R, van Geel M: Cryptic Splicing At A Non-consensus Splice-donor Site In A Patient With A New Mutation In The Plakophilin-1 Gene. *Pediatric Dermatology* 2004, 21:415.
107. Steijlen PM, Van Steensel MA, Jansen BJ, **Blokk** W, Van De Kerkhof PC, Happle R, van Geel M: Cryptic splicing at a non-consensus splice-donor in a patient with a novel mutation in the plakophilin-1 gene. *Journal of Investigative Dermatology* 2004, 122:1321–1324.
108. **Blokk** WA, Smit JV, de Wilde PC, van de Kerkhof PC, Ruiters DJ, de Jong EM: Immunohistochemical effects of temporary cessation of long-term acitretin treatment in keratinocytic intraepidermal neoplasia of renal transplant recipients. *Archives of Dermatology* 2003, 139:671–673.
109. **Blokk** WA, de Jong EM, de Wilde PC, Bulten J, Link MM, Ruiters DJ, van de Kerkhof PC: P16 and p53 expression in (pre) malignant epidermal tumors of renal transplant recipients and immunocompetent individuals. *Modern Pathology* 2003, 16:869–878.
110. **Blokk** WA, Smit JV, Wilde PC de, Kerkhof PCV de, Ruiters DJ, Jong EM de: CORRESPONDENCE: VIGNETTES-Immunohistochemical Effects of Temporary Cessation of Long-term Acitretin Treatment in Keratinocytic Intraepidermal Neoplasia of Renal Transplant Recipients. *Archives of Dermatology* 2003, 139:671–676.
111. Tjioe M, Smits T, **Blokk** WA, Van De Kerkhof P, Gerritsen M-JP: High-dose long wave visible light induces perinuclear vacuolization in vivo but does not result in early photoageing and apoptosis. *Experimental Dermatology* 2003, 12:610–614.
112. Smits T, Tjioe M, **Blokk** W, Van De Kerkhof P, Gerritsen M: High dose long wave visible light induces perinuclear vacuolization in vivo. 2002, 119:739–739.
113. **Blokk** WA, Smit JV, de Jong EMG, Link MM, van de Kerkhof PC, Ruiters DJ: Retinoids strongly and selectively correlate with keratin 13 and not keratin 19 expression in cutaneous warts of renal transplant recipients. *Archives of Dermatology* 2002, 138:61–65
114. **Blokk** WA, Andriessen MP, van Hamersvelt HW, van Krieken JH: Initial spontaneous remission of posttransplantation Epstein Barr virus-related B-cell lymphoproliferative disorder of the skin in a renal transplant recipient: case report and review of the literature on cutaneous B-cell posttransplantation lymphoproliferative disease. *The American Journal of Dermatopathology* 2002, 24:414–422.
115. Smit JV, Cox S, **Blokk** W, Van De Kerkhof P, de Jongh GJ, De Jong E: Actinic keratoses in renal transplant recipients do not improve with calcipotriol cream and all-trans retinoic acid cream as monotherapies or in combination during a 6-week treatment period. *British Journal of Dermatology* 2002, 147:816–818.
116. **Blokk** W, Rasing L, Veth R, Pruszczynski M: Late malignant transformation of biopsy proven benign synovial chondromatosis: an unexpected pitfall. *Histopathology* 2000, 36:564–566